All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear from you! 📣

(You can also reach out to me on LinkedIn)

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

THE GOOD
Approvals & Labels

AbbVie makes giant attempt for Rinvoq label expansion; applies for EMA and FDA approval
Small molecule, giant cell arteritis - Read more

THE GOOD
Clinical Trials

Immutep posts stellar Ph2b carcinoma clinical data
Protein, large molecule, head & neck cancer - Read more

Know Labs’ positive early clinical data for their needle-free glucose monitoring device
Medical device, glucose monitoring, diabetes - Read more

THE GOOD
Company Launches

ImmuneAGE Bio launches with $2M, HSC bone marrow drug discovery
Drug discovery, small molecule, hematopoietic stem cell, immune system - Read more 

THE GOOD
Fundraises

IDEAYA Biosciences raise over $300M in public offering after positive Ph2 solid tumor data
Small molecule, urothelial cancer, lung cancer - Read more

THE GOOD
Investments

Dynamic Cell Therapies handed $1M investment from Myeloma Investment Fund (MIF)
CAR-T cell therapy, multiple myeloma, cancer - Read more

THE GOOD
IPOs

SIM Acquisition I & Launch One Acquisition launch as both raised $200M, healthcare-focused SPACs
Healthcare investing, special purpose acquisition company - Read more

THE GOOD
Mergers & Acquisitions

Eli Lilly-invested healthcare VC Unseen Capital acquired by Seae Ventures
Venture capital, healthcare investing, marginalized communities - Read more

Merz Therapeutics is “keenly interested in acquiring late-stage assets in rare neurology”
Small molecule amino acid, Parkinson’s, multiple sclerosis (MS) - Read more

THE GOOD
Opinions

Rising tide lifts all boats; Pfizer’s oral small molecule obesity announcement lifts Viking Therapeutics and Terns Pharmaceuticals stocks
Small molecule, obesity - Read more

THE GOOD
Research

Another potential W for Novo Nordisk’s Ozempic, as regular semaglutide use linked with lower dementia risk in those with Type 2 diabetes
GLP-1, diabetes, dementia - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Layoffs

Spark Therapeutics loses spark for laid off R&D staff
Gene therapy, structural reorg - Read more

THE BAD
Market Reports

Biosimilars continue chipping away at AbbVie’s Humira dominance
Monoclonal antibody, autoimmune, biosimilar - Read more

At least one analyst firm isn’t bullish on Bristol Myers Squibb’s future - Read more

THE UGLY
Patient Access

Not so fast; Big Pharma isn’t off the drug price hook, even as the FTC hammers down on PBMs
Drug pricing, Federal Trade Commission, Pharmacy Benefit Manager - Read more

THE UGLY
Politics & Policy

FDA’s authority post-Chevron could be first tested against lab-developed test ruling
Chevron doctrine, lab-development tests, diagnostics - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.